Granules Pharmaceuticals Inc.April 3, 2026

FDA 483 - Granules Pharmaceuticals Inc. - April 03, 2026

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Granules Pharmaceuticals Inc.

Record Details

An FDA inspection of Granules Pharmaceuticals Inc. in Chantilly, VA, revealed significant deficiencies in quality control and facility maintenance. The firm failed to adequately investigate recurring stability failures and uncharacterized impurities, and did not consistently adhere to its written stability testing program. Additionally, issues were noted with incomplete batch production records and critical HVAC equipment failures leading to product contamination.

Company: Granules Pharmaceuticals Inc.
Inspection Date: April 3, 2026
Product Type: Drugs
Office: Office of Regulatory Affairs
People: David A. Oluwo (Pharmacy Intern/Certified Pharmacy Technician)
Ofuje D. Daniyan

Open in Dashboard

ID · d8b4fccb-5ec0-4d32-b070-267fbae547e0